Wet Age-Related Macular Degeneration Market

Wet Age Related Macular Degeneration market Segmentation Analysis

The global Wet Age Related Macular Degeneration market is bifurcated three segments, by drug type, by route of administration and region. By drug type, the market is bifurcated into anti-vegf drugs, complementary therapies, and gene therapy. By route of administration, the market is bifurcated into intravitreal injections, sub retinal injections, oral medications and region. [caption id="attachment_34709" align="aligncenter" width="1920"] Wet Age-Related Macular Degeneration Market | Exactitude Consultancy[/caption] Based on device type, the market is bifurcated into anti-vegf drugs, complementary therapies, and gene therapy. Anti-VEGF medications account for 85% of the Wet AMD market. These medications, including as Lucentis, Avastin, and Eylea, function by inhibiting the formation of aberrant blood vessels that lead to vision loss in wet AMD. Their efficacy and well-established treatment methods reinforce their position as the key drivers of market expansion. Complementary treatments, which include medications that target inflammation and oxidative stress, presently account for roughly 10% of the market. While they do not directly target blood vessel development, they can help manage related problems and perhaps improve treatment results. With further research and development in this field, their market share is likely to grow. Gene therapy remains an emerging industry with enormous promise, but it presently has a tiny market share, estimated at under 5%. These medicines attempt to target the underlying genetic etiology of wet AMD, perhaps providing a long-term or possibly curative therapy. However, they are still in the early phases of research and will require more clinical trials and regulatory approval before general usage. Longer-lasting or more effective anti-VEGF medications may diminish their market share marginally, but they are expected to stay dominant for the near future. [caption id="attachment_34710" align="aligncenter" width="1920"] Wet Age-Related Macular Degeneration Market | Exactitude Consultancy[/caption] The Wet Age-Related Macular Degeneration (Wet AMD) market is segmented by administration method, providing a diverse variety of therapeutic choices. Intravitreal injections, which include the direct injection of medicine into the vitreous cavity of the eye, are the most common and commonly used method of treating Wet AMD. Anti-VEGF drugs, such as ranibizumab or aflibercept, are often delivered directly to the site of aberrant blood vessel development, preventing progression and maintaining vision. Sub retinal injections, another available method of administration, include the targeted delivery of therapeutic substances beneath the retina. While less frequent than intravitreal injections, sub retinal methods may be used for select types of Wet AMD, allowing for precision therapy delivery to the afflicted retinal layers. In addition to injection-based therapy, oral medicines are available as an additional mode of delivery. Oral therapies try to cure Wet AMD by altering biological processes involved in angiogenesis and inflammation. [caption id="attachment_34711" align="aligncenter" width="1920"] Wet Age-Related Macular Degeneration Market | Exactitude Consultancy[/caption] While injectable treatments are more common, oral drugs provide a systemic approach to controlling the illness. Each method of administration has its own set of effectiveness, safety, and patient convenience concerns. Intravitreal injections are frequently preferred for their focused delivery and quick beginning of action, while sub retinal injections and oral drugs may be considered if particular patient demands or features dictate a different strategy. The variety of administration methods highlights the dynamic character of the Wet AMD market, giving healthcare practitioners with a variety of instruments to adapt treatment plans to each patient's particular needs. As research and clinical trials progress, the market is anticipated to see more breakthroughs and refinements in the different methods of administration, leading to the continued evolution of Wet AMD therapy.

Wet Age Related Macular Degeneration Market Dynamics

Driver The increased incidence of Wet Age-Related Macular Degeneration can be attributed to a combination of lifestyle factors. Scientific research have repeatedly connected these modifiable risk factors to an increased possibility of acquiring AMD, particularly the wet type of the illness. For example, smoking has been recognized as a substantial risk factor because it causes oxidative stress and inflammation in the retina, which contributes to the advancement of AMD. Poor dietary habits, which include a lack of vital nutrients such as antioxidants and omega-3 fatty acids, have also been linked to an increased risk of AMD development. A diet lacking in fruits, vegetables, and seafood, which are high in these preventive chemicals, may jeopardize macula health and increase sensitivity to AMD. Sedentary behavior and a lack of regular physical activity have also been related to an increased risk of AMD. A sedentary lifestyle may contribute to obesity and other systemic health disorders, enhancing the chance of acquiring eye-related diseases. The greater knowledge of these lifestyle-related risk factors plays a critical role in the increased prevalence of AMD. As public health campaigns and educational programs highlight the link between these habits and eye health, more people are becoming aware of the preventative steps they may take. This increased knowledge motivates individuals to seek early diagnosis and treatment, as they appreciate the value of preventive eye care in protecting eyesight. Restraint The high treatment costs associated with Wet AMD, particularly in the context of anti-VEGF (vascular endothelial growth factor) therapies, present a substantial financial challenge. These advanced therapies have shown extraordinary success in controlling Wet AMD, frequently stabilizing or even improving vision. However, the costs associated with their research, manufacture, and administration have resulted in a scenario in which access to these medicines is limited due to financial constraints. For patients, the financial burden of Wet AMD therapies might be daunting. The requirement for repeated intravitreal injections, a popular delivery technique for anti-VEGF medicines, raises the total cost. Many people with Wet AMD require continuing treatment, and the accumulated costs can put a strain on personal resources, potentially affecting their quality of life. Furthermore, the financial concerns may contribute to treatment non-adherence, since some patients may avoid or delay treatments owing to financial restrictions, endangering the therapy's efficacy. Opportunities The field of Wet Age-Related Macular Degeneration is witnessing a promising era of innovation driven by ongoing research into novel therapeutic approaches. Wet Age-Related Macular Degeneration (Wet AMD) is entering a bright period of innovation, fueled by continuous research into innovative treatment methods. Beyond the well-established standard of anti-VEGF (vascular endothelial growth factor) medications, researchers are looking into novel approaches that have the potential to change the therapy landscape for Wet AMD. This dynamic investigation covers the development of alternative medications, gene treatments, and regenerative medicine techniques, all with the common objective of finding more focused and long-lasting remedies for this vision-threatening disorder. One field of investigation is the identification and development of alternative medications that target distinct pathways involved in the development and progression of Wet AMD. These may include innovative pharmacological medicines targeted to address specific features of the condition, perhaps with greater efficacy or lower adverse effects when compared to conventional therapies. The diversity of methods attempts to give physicians and patients with a larger choice of therapeutic alternatives, allowing for more tailored and successful treatment programs.

Wet Age Related Macular Degeneration Market Trends

• The market continues to see advancements in anti-vascular endothelial growth factor (anti-VEGF) pharmaceuticals, with the launch of new agents and formulations. These treatments are designed to prevent aberrant blood vessel proliferation, which is a feature of Wet AMD.
• The field is evolving toward more personalized medicine, with efforts to modify treatment techniques based on specific patient features, genetic profiles, and response to medicines. This tendency reflects a greater awareness of the variability of Wet AMD.
• Beyond typical anti-VEGF medications, researchers are looking for new therapy techniques. Combination therapy, gene therapies, and sustained-release drug delivery systems are examples of treatments that try to improve efficacy while reducing the stress of repeated injections.
• Adoption of telemedicine and digital health solutions for remote monitoring, early detection, and increasing treatment adherence: The integration of technology is playing a crucial role in patient management, with the adoption of telemedicine and digital health solutions for remote monitoring, early detection, and improving treatment adherence.
• Imaging technology advancements, like as optical coherence tomography (OCT) and angiography, aid in the earlier and more accurate diagnosis of Wet AMD. Early identification is critical for prompt intervention and improved results.
• Initiatives and collaborations have been established to provide access to effective therapies, particularly in emerging nations where the prevalence of AMD is increasing. This includes tackling cost, infrastructural and healthcare delivery challenges.
• There is a rising emphasis on patient-centered methods, which examine not just the clinical efficacy of therapies but also their effects on patients' entire quality of life. This involves treating the psychological and functional elements of visual loss.

Competitive Landscape

The competitive landscape of the Wet Age Related Macular Degeneration market was dynamic, with several prominent companies competing to provide innovative and advanced Wet Age Related Macular Degeneration solutions.

1. Genentech
2. Regeneron Pharmaceuticals
3. Novartis
4. Bayer
5. Allergan
6. Ophthotech Corporation
7. Alcon
8. Iveric Bio
9. Santen Pharmaceutical
10. Kodiak Sciences
11. Graybug Vision
12. Opthea Limited
13. Gilead Sciences
14. Ocular Therapeutix
15. PanOptica
16. Tyrogenex
17. Novo Nordisk
18. Adverum Biotechnologies
19. OphthaliX Inc.
20. Polyphor AG

Recent Developments:

December 11, 2023- Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) April 14, 2019- Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio.

Regional Analysis

North America, particularly the United States, has a greater prevalence of wet AMD than other regions due to an aging population and specific lifestyle variables. This results into a higher market size and increased demand for treatment solutions. North America has well-developed healthcare systems with access to a wide range of specialists and cutting-edge technology. This provides early diagnosis, effective treatment, and better patient outcomes, boosting market expansion even further. When compared to other locations, North American patients have more disposable resources, allowing them to afford the often-expensive wet AMD therapies, such as anti-VEGF medications and specialist injections. North America is a center for medical and pharmaceutical research, which has resulted in continual innovation and development of novel diagnostic tools, treatment alternatives, and delivery modalities for wet AMD. This maintains the region's market leadership and draws investment from both domestic and foreign firms. When compared to other locations, insurance coverage for wet AMD therapies is often more thorough in North America. This decreases the financial burden on patients and stimulates earlier intervention, which strengthens market development even more. With its increasing aging population and increased healthcare spending, Asia-Pacific is expected to be the fastest-growing market for wet AMD therapy. China, Japan, and India are major participants in this region. [caption id="attachment_34712" align="aligncenter" width="1920"] Wet Age-Related Macular Degeneration Market | Exactitude Consultancy[/caption]

Target Audience for Wet Age Related Macular Degeneration Market

• Patients and Caregivers
• Ophthalmologists and Eye Care Professionals
• Pharmaceutical and Biotechnology Companies
• Investors and Stakeholders
• Regulatory Authorities
• Healthcare Providers and Hospitals
• Research Institutions and Academia
• Patient Advocacy Groups
• Insurance Providers and Payers
• Government Health Agencies

Segments Covered in the Wet Age Related Macular Degeneration Market Report

Wet Age Related Macular Degeneration Market by Drug Type

• Anti-VEGF drugs
• Complementary therapies
• Gene therapy

Wet Age Related Macular Degeneration Market by Route of Administration

• Intravitreal injections
• Sub retinal injections
• Oral medications

Wet Age Related Macular Degeneration Market by Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East and Africa

Key Question Answered

• What is the expected growth rate of the Wet Age Related Macular Degeneration market over the next 7 years?
• Who are the key market participants in Wet Age Related Macular Degeneration, and what are their market share?
• What are the end-user industries driving market demand and what is their outlook?
• What are the opportunities for growth in emerging markets such as Asia-Pacific, the Middle East, and Africa?
• How is the economic environment affecting the Wet Age Related Macular Degeneration market, including factors such as interest rates, inflation, and exchange rates?
• What is the expected impact of government policies and regulations on the Wet Age Related Macular Degeneration market?
• What is the current and forecasted size and growth rate of the global Wet Age Related Macular Degeneration market?
• What are the key drivers of growth in the Wet Age Related Macular Degeneration market?
• Who are the major players in the market and what is their market share?
• What are the distribution channels and supply chain dynamics in the Wet Age Related Macular Degeneration market?
• What are the technological advancements and innovations in the Wet Age Related Macular Degeneration market and their impact on product development and growth?
• What are the regulatory considerations and their impact on the market?
• What are the challenges faced by players in the Wet Age Related Macular Degeneration market and how are they addressing these challenges?
• What are the opportunities for growth and expansion in the Wet Age Related Macular Degeneration market?
• What are the product offerings and specifications of leading players in the market?

1. INTRODUCTION
   
   
   
   1. MARKET DEFINITION
   
   
   2. MARKET SEGMENTATION
   
   
   3. RESEARCH TIMELINES
   
   
   4. ASSUMPTIONS AND LIMITATIONS
   
   
   
   


2. RESEARCH METHODOLOGY
   
   
   
   1. DATA MINING
      
      
      
      1. SECONDARY RESEARCH
      
      
      2. PRIMARY RESEARCH
      
      
      3. SUBJECT-MATTER EXPERTS’ ADVICE
      
      
      
      
   
   
   2. QUALITY CHECKS
      
      
      
      1. FINAL REVIEW
      
      
      
      
   
   
   3. DATA TRIANGULATION
      
      
      
      1. BOTTOM-UP APPROACH
      
      
      2. TOP-DOWN APPROACH
      
      
      3. RESEARCH FLOW
      
      
      
      
   
   
   4. DATA SOURCES
   
   
   
   


3. EXECUTIVE SUMMARY


4. MARKET OVERVIEW
   
   
   
   1. WET AGE RELATED MACULAR DEGENERATION MARKET OUTLOOK
      
      
      
      1. MARKET DRIVERS
      
      
      2. MARKET RESTRAINTS
      
      
      3. MARKET OPPORTUNITIES
      
      
      
      
   
   
   2. IMPACT OF COVID-19 ON WET AGE RELATED MACULAR DEGENERATION MARKET
   
   
   3. PORTER’S FIVE FORCES MODEL
      
      
      
      1. THREAT FROM NEW ENTRANTS
      
      
      2. THREAT FROM SUBSTITUTES
      
      
      3. BARGAINING POWER OF SUPPLIERS
      
      
      4. BARGAINING POWER OF CUSTOMERS
      
      
      5. DEGREE OF COMPETITION
      
      
      
      
   
   
   4. INDUSTRY VALUE CHAIN ANALYSIS
   
   
   
   


5. GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE, 2020-2030, (USD BILLION)
   
   
   
   1. ANTI-VEGF DRUGS
   
   
   2. COMPLEMENTARY THERAPIES
   
   
   3. GENE THERAPY
   
   
   
   


6. GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION, 2020-2030, (USD BILLION)
   
   
   
   1. INTRAVITREAL INJECTIONS
   
   
   2. SUBRETINAL INJECTIONS
   
   
   3. ORAL MEDICATIONS
   
   
   
   


7. GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY REGION, 2020-2030, (USD BILLION)
   
   
   
   1. NORTH AMERICA
      
      
      
      1. US
      
      
      2. CANADA
      
      
      3. MEXICO
      
      
      
      
   
   
   2. SOUTH AMERICA
      
      
      
      1. BRAZIL
      
      
      2. ARGENTINA
      
      
      3. COLOMBIA
      
      
      4. REST OF SOUTH AMERICA
      
      
      
      
   
   
   3. EUROPE
      
      
      
      1. GERMANY
      
      
      2. UK
      
      
      3. FRANCE
      
      
      4. ITALY
      
      
      5. SPAIN
      
      
      6. RUSSIA
      
      
      7. REST OF EUROPE
      
      
      
      
   
   
   4. ASIA PACIFIC
      
      
      
      1. INDIA
      
      
      2. CHINA
      
      
      3. JAPAN
      
      
      4. SOUTH KOREA
      
      
      5. AUSTRALIA
      
      
      6. SOUTH-EAST ASIA
      
      
      7. REST OF ASIA PACIFIC
      
      
      
      
   
   
   5. MIDDLE EAST AND AFRICA
      
      
      
      1. UAE
      
      
      2. SAUDI ARABIA
      
      
      3. SOUTH AFRICA
      
      
      4. REST OF MIDDLE EAST AND AFRICA
      
      
      
      
   
   
   
   

8. COMPANY PROFILES*

(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)

1. GENENTECH


2. REGENERON PHARMACEUTICALS


3. NOVARTIS


4. BAYER


5. ALLERGAN


6. OPHTHOTECH CORPORATION


7. ALCON


8. IVERIC BIO


9. SANTEN PHARMACEUTICAL


10. KODIAK SCIENCES


11. GRAYBUG VISION


12. OPTHEA LIMITED


13. GILEAD SCIENCES


14. OCULAR THERAPEUTIX


15. PANOPTICA


16. TYROGENEX


17. NOVO NORDISK


18. ADVERUM BIOTECHNOLOGIES


19. OPHTHALIX INC.


20. POLYPHOR AG

*THE COMPANY LIST IS INDICATIVE

LIST OF TABLES

TABLE 1 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 2 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 3 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY REGION (USD BILLION) 2020-2030

TABLE 4 NORTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 5 NORTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 6 NORTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 7 US WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 8 US WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 9 CANADA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 10 CANADA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 11 MEXICO WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 12 MEXICO WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 13 SOUTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 14 SOUTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 15 SOUTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 16 BRAZIL WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 17 BRAZIL WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 18 ARGENTINA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 19 ARGENTINA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 20 COLOMBIA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 21 COLOMBIA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 22 REST OF SOUTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 23 REST OF SOUTH AMERICA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 24 ASIA-PACIFIC WET AGE RELATED MACULAR DEGENERATION MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 25 ASIA-PACIFIC WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 26 ASIA-PACIFIC WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 27 INDIA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 28 INDIA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 29 CHINA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 30 CHINA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 31 JAPAN WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 32 JAPAN WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 33 SOUTH KOREA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 34 SOUTH KOREA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 35 AUSTRALIA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 36 AUSTRALIA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 37 SOUTH-EAST ASIA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 38 SOUTH-EAST ASIA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 39 REST OF ASIA PACIFIC WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 40 REST OF ASIA PACIFIC WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 41 EUROPE WET AGE RELATED MACULAR DEGENERATION MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 42 EUROPE WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 43 EUROPE WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 44 GERMANY WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 45 GERMANY WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 46 UK WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 47 UK WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 48 FRANCE WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 49 FRANCE WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 50 ITALY WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 51 ITALY WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 52 SPAIN WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 53 SPAIN WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 54 RUSSIA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 55 RUSSIA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 56 REST OF EUROPE WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 57 REST OF EUROPE WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 58 MIDDLE EAST AND AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 59 MIDDLE EAST AND AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 60 MIDDLE EAST AND AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 61 UAE WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 62 UAE WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 63 SAUDI ARABIA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 64 SAUDI ARABIA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 65 SOUTH AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 66 SOUTH AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

TABLE 67 REST OF MIDDLE EAST AND AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE (USD BILLION) 2020-2030

TABLE 68 REST OF MIDDLE EAST AND AFRICA WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030

LIST OF FIGURES

FIGURE 1 MARKET DYNAMICS

FIGURE 2 MARKET SEGMENTATION

FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 4 DATA TRIANGULATION

FIGURE 5 BOTTOM-UP APPROACH

FIGURE 6 TOP-DOWN APPROACH

FIGURE 7 RESEARCH FLOW

FIGURE 8 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE, USD BILLION, 2022-2030

FIGURE 9 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION, USD BILLION, 2022-2030

FIGURE 10 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY REGION, USD BILLION, 2022-2030

FIGURE 11 PORTER’S FIVE FORCES MODEL

FIGURE 12 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY DRUG TYPE, USD BILLION,2022

FIGURE 13 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION, USD BILLION,2022

FIGURE 14 GLOBAL WET AGE RELATED MACULAR DEGENERATION MARKET BY REGION, USD BILLION,2022

FIGURE 15 MARKET SHARE ANALYSIS

FIGURE 16 GENENTECH: COMPANY SNAPSHOT

FIGURE 17 REGENERON PHARMACEUTICALS: COMPANY SNAPSHOT

FIGURE 18 NOVARTIS: COMPANY SNAPSHOT

FIGURE 19 BAYER: COMPANY SNAPSHOT

FIGURE 20 ALLERGAN: COMPANY SNAPSHOT

FIGURE 21 OPHTHOTECH CORPORATION: COMPANY SNAPSHOT

FIGURE 22 ALCON: COMPANY SNAPSHOT

FIGURE 23 IVERIC BIO: COMPANY SNAPSHOT

FIGURE 24 SANTEN PHARMACEUTICAL: COMPANY SNAPSHOT

FIGURE 25 KODIAK SCIENCES: COMPANY SNAPSHOT

FIGURE 26 GRAYBUG VISION: COMPANY SNAPSHOT

FIGURE 27 OPTHEA LIMITED: COMPANY SNAPSHOT

FIGURE 28 GILEAD SCIENCES: COMPANY SNAPSHOT

FIGURE 29 OCULAR THERAPEUTIX: COMPANY SNAPSHOT

FIGURE 30 PANOPTICA: COMPANY SNAPSHOT

FIGURE 31 TYROGENEX: COMPANY SNAPSHOT

FIGURE 32 NOVO NORDISK: COMPANY SNAPSHOT

FIGURE 33 ADVERUM BIOTECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 34 OPHTHALIX INC.: COMPANY SNAPSHOT

FIGURE 35 POLYPHOR AG